Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Maintenance on feeder cells
What ifWhat if pluripotent stem cells grow on a layer of growth-arrested fibroblasts during maintenance?
Claim language“in the absence of feeder cells”
Growth-arrested fibroblasts provide an attachment surface and secrete factors that support pluripotent colony growth. Pluripotent colonies are lifted from the feeder layer and dissociated before transfer to suspension culture.
1.3Posterior patterning with growth factors
What ifWhat if fibroblast growth factor 8 and growth differentiation factor 11 provide positional cues during this stage in a retinoic-acid-free medium?
Claim language“culture medium containing retinoic acid”
The aggregates remain in suspension while fibroblast growth factor 8 provides a caudalizing signal to neural progenitors. Growth differentiation factor 11 shifts expression toward more posterior HOX genes, and the HOX expression profile provides a readout of positional identity before ventral patterning.
1.4Direct transcription factor induction
What ifWhat if inducible expression of OLIG2 and NKX2.2 provides ventral glial specification while the medium contains retinoic acid and lacks SHH signaling activators?
Claim language“one or more SHH signaling activators”
The starting pluripotent cells carry inducible expression cassettes for OLIG2 and NKX2.2. Inducing the cassettes during aggregate culture supplies two transcription factors associated with ventral oligodendrocyte progenitor specification.
1.5Low-dose retinoic acid maintenance
What ifWhat if the proliferation medium retains a reduced concentration of retinoic acid during continued SHH activation?
Claim language“containing no retinoic acid”
A medium exchange lowers retinoic acid from the preceding patterning concentration to a low, nonzero concentration. An SHH activator continues to support ventral identity, and platelet-derived growth factor AA supports expansion of responsive glial progenitors within the aggregates.
1.6Aggregate culture on a membrane
What ifWhat if intact aggregates rest on a porous membrane during the final culture stage?
Claim language“to suspension culture”
A laminin-coated porous insert supports each aggregate at a fixed location. Medium supplied beneath the membrane contains neither retinoic acid nor an SHH signaling activator, and soluble nutrients reach the attached aggregates through the pores.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Aggregate assay for material extracts
A medical materials testing laboratory uses glial progenitor aggregates from the staged suspension culture as test specimens for material extracts. A low-attachment assay plate holds one aggregate per well, with wells assigned to extract exposure, extraction vehicle, or culture medium controls. After exposure, imaging records aggregate size and morphology, and a viability assay measures the response relative to the vehicle control.
Component substitution
Carrier-free aggregation in stirred suspension
A low-shear stirred vessel replaces the static vessel used for embryoid body formation. Feeder-free pluripotent stem cells enter the vessel in the initial medium, and impeller circulation keeps the forming aggregates suspended without carrier particles. At each medium transition, the aggregates settle in a sterile transfer vessel before the spent medium is withdrawn and the next medium is added.
Parameter or scale variation
Parallel culture across two working volumes
Six identical 50 mL suspension vessels run in parallel, with three filled to 15 mL and three filled to 30 mL. All vessels start at the same viable cell concentration, so each 30 mL vessel receives twice as many cells as each 15 mL vessel. The vessels follow the same sequence of media and exchange times, with replacement volumes matched to their working volumes. Endpoint sampling records aggregate count per milliliter and the diameter distribution for each vessel.
Combination with existing systems
Suspension culture with membrane perfusion
An aggregate culture chamber connects to a perfusion loop through a membrane that passes medium and retains the aggregates. A feed manifold selects a reservoir containing the formulation for the current culture stage, and a pump supplies fresh medium while spent medium exits to waste. At a stage transition, the manifold primes the new feed line to waste before directing the selected formulation into the chamber.
Automated or data-driven variant
Image-based aggregate size tracking
An incubator-compatible bright-field camera images the same positions in each suspension culture vessel at scheduled intervals. Software segments aggregate outlines and calculates the projected-area diameter and count for each field. The software flags fused aggregates and cultures whose diameter distribution exceeds a configured limit, and stores the images and measurements with the corresponding medium stage.
Robotic medium exchanges after settling
A liquid-handling robot uses a low-attachment culture plate and separate reservoirs for the successive medium formulations. At each scheduled exchange, the robot pauses plate motion for aggregate settling, aspirates spent medium from the upper liquid layer, and dispenses the next formulation against the well wall. The controller records the reservoir identity and dispensed volume for each well and reports wells with failed transfers.
Specific version of a part
Defined laminin maintenance surface
Pluripotent stem cell colonies attach to a surface coated with recombinant laminin-521. A defined maintenance medium containing fibroblast growth factor 2 and transforming growth factor beta supports colony expansion in the absence of feeder cells.
All-trans retinoic acid exposure
A medium exchange transfers the aggregates into embryoid-body-forming medium containing all-trans retinoic acid. The retinoic acid stock remains shielded from light during preparation, and the aggregates remain in low-attachment wells during exposure.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1(1) a step of subjecting pluripotent stem cells to maintenance culture in the absence of feeder cells,
1.2(2) a step of subjecting pluripotent stem cells obtained in (1) to suspension culture in an embryoid-body-forming culture medium containing one or more SMAD signaling inhibitors and one or more Wnt signaling activators in the absence of feeder cells for 5 days to 10 days, to form a cell aggregate;
In the absence of substrate, cells lift off the floor of the flask and continue to proliferate in suspension forming a hollow sphere of undifferentiated cells. After approximately 3-10 days in vitro, the proliferating clusters (neurospheres) are fed every 2-7 days, and more particularly every 24 days by gentle centrifugation and resuspension in medium containing growth factor.
A · US 2006/0287385 A1 · ¶ 498
Differentiation and enrichment of neuroectodermal cells. hESC colonies were detached from MEF layer by the treatment of the culture with 0.2 mg/ml of dispase (Roche Diagnostics) and grown as floating cell aggregates (embryoid body) for four days with a daily change of ESC medium.
B · US 8,153,424 B2 · ¶ 123
1.3(3) a step of subjecting the cell aggregate obtained in (2) to suspension culture in an embryoid-body-forming culture medium containing retinoic acid;
(c) expanding the resulting cells of step (b) in a suspension culture with a sufficient amount of retinoic acid; and (d) culturing the cells of step (c) in a suspension culture with a sufficient amount of retinoic acid and an agent selected from the group consisting of sonic hedgehog and purmorphamine, wherein at least 80% of the resulting cells are Olig2+, Nkx2.2+, Irx3+ and Pax7−.
B · US 8,153,424 B2 · claim 1
1.4(4) a step of subjecting the cell aggregate obtained in (3) to suspension culture in an embryoid-body-forming culture medium or neuron-and-glia-proliferating culture medium containing retinoic acid and one or more SHH signaling activators; and
According to the present invention, large numbers of non-tumorigenic neural progenitor cells can be perpetuated in vitro and their rate of proliferation and/or differentiation can be affected by contact with hedgehog agonists of the present invention.
A · US 2006/0287385 A1 · ¶ 487
(c) expanding the resulting cells of step (b) in a suspension culture with a sufficient amount of retinoic acid; and (d) culturing the cells of step (c) in a suspension culture with a sufficient amount of retinoic acid and an agent selected from the group consisting of sonic hedgehog and purmorphamine, wherein at least 80% of the resulting cells are Olig2+, Nkx2.2+, Irx3+ and Pax7−.
B · US 8,153,424 B2 · claim 1
1.5(5) a step of subjecting the cell aggregate obtained in (4) to suspension culture in a neuron-and-glia-proliferating culture medium containing no retinoic acid and one or more SHH signaling activators, and optionally further comprising:
According to the present invention, large numbers of non-tumorigenic neural progenitor cells can be perpetuated in vitro and their rate of proliferation and/or differentiation can be affected by contact with hedgehog agonists of the present invention.
A · US 2006/0287385 A1 · ¶ 487
This highly improved ventral spinal progenitor and motor neuron induction over our previous method is due to continued presence of SHH in a suspension culture that promotes proliferation of the Olig2-expressing progenitors.
B · US 8,153,424 B2 · ¶ 5
1.6(6) a step of subjecting the cell aggregate obtained in (5) to suspension culture in a neuron-and-glia-proliferating culture medium containing neither retinoic acid nor an SHH signaling activator.
The second step is to culture the spinal cord progenitors in the presence of sonic hedgehog (SHH, 50-250 ng/ml) for 6-7 days to induce a ventralized progenitor character, as evidenced by expression of Olig2, (FIG. 11F, G, H), a transcription factor expressed by only ventral neural progenitors, then in the regular neuronal differentiation medium for additional 7-10 days until spinal motor neurons develop.
B · US 8,153,424 B2 · ¶ 59
An empty cell means only that no passage was reproduced there.
Statements in these documents
Given the critical inductive roles of hedgehog polypeptides in the development and maintenance of vertebrate organs, the identification of hedgehog interacting proteins is of paramount significance in both clinical and research contexts.
A · US 2006/0287385 A1 · ¶ 5
Needed in the art is a simple, yet efficient, strategy for the isolation of transplantable neural and motor neuron precursors from differentiating human ES cell cultures.
B · US 8,153,424 B2 · ¶ 4
The new differentiation strategy, even without further purification, facilitates the basic and translational studies employing human motor neurons at a minimal cost.
B · US 8,153,424 B2 · ¶ 5
Cite aspatent.fyi, US 2026/0355252 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355252/, SHA-256 03d8e09e7a2147f2a1eafb8c694f1ab7d5d07bbdee34c5d5050b2266979740a4